6,268 results on '"positron emission tomography (PET)"'
Search Results
52. PET imaging of synaptic vesicle glycoprotein 2 subtype A for neurological recovery in ischemic stroke
- Author
-
Luo, Xiaoyun, Jin, Chentao, Chen, Hetian, Niu, Jiaqi, Yu, Congcong, Dou, Xiaofeng, Wang, Jing, Wen, Junjie, Zhang, Hong, Tian, Mei, and Zhong, Yan
- Published
- 2024
- Full Text
- View/download PDF
53. Total-body dynamic PET/CT imaging reveals kinetic distribution of [13N]NH3 in normal organs
- Author
-
Liu, Guobing, Gu, Taoying, Chen, Shuguang, Gu, Yushen, Yu, Haojun, and Shi, Hongcheng
- Published
- 2024
- Full Text
- View/download PDF
54. Radiolabeled imaging agents for Alzheimer's disease
- Author
-
Jiajun Wu, Kexin Li, Jie Yang, Meiting Mao, and Yan Cheng
- Subjects
Alzheimer's disease (AD) ,β‐amyloid (Aβ) ,molecular probe ,neuroinflammation ,positron emission tomography (PET) ,tau ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disorder with long preclinical and prodromal phases in older people. Molecular imaging is a promising approach for noninvasive in vivo identification and tracking pathophysiological changes. In particular, nuclear neuroimaging in AD has extended beyond traditional evaluation of brain perfusion and glucose metabolism, and has achieved substantial progress over the past 2 decades. To gain a comprehensive understanding of nuclear neuroimaging with different targets in the brain, this review provides an overview of the literature on the current status and recent progress of the development of radioligands for definitive and differential diagnosis of AD.
- Published
- 2024
- Full Text
- View/download PDF
55. Targeting colony‐stimulating factor 1 receptor: From therapeutic drugs to diagnostic radiotracers
- Author
-
Xiaochuan Zha, Wenxue Hui, Dengfeng Cheng, Hongcheng Shi, and Zonghua Luo
- Subjects
colony‐stimulating factor 1 receptor (CSF1R) ,CSF1R inhibitor ,neuroinflammation imaging ,positron emission tomography (PET) ,radiotracer ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Colony‐stimulating factor 1 receptor (CSF1R) is highly expressed in mononuclear phagocytes and in the central nervous system. It has emerged as a promising target for tumor therapy and neuroinflammation imaging. Although therapeutic agents targeting CSF1R have shown great success, the development of diagnostic radiotracers for CSF1R has faced numerous challenges. Consequently, there is an urgent need to overcome these obstacles for the development of CSF1R radiotracers, particularly positron emission tomography tracers, not only for diagnostic purposes but also to aid the development of more effective therapeutic drugs. Here, we provide a comprehensive overview of the development of CSF1R radiotracers, presenting detailed profiles of each tracer's ability to image CSF1R. Additionally, we discuss reported CSF1R small‐molecule inhibitors and antibodies, highlighting their relevance to the further development of CSF1R radiotracers. We aim to shed light on the current state of CSF1R radiotracer research and development, provide an insight into the challenges in this field, and offer guidance for future exploration.
- Published
- 2024
- Full Text
- View/download PDF
56. Head-to-head comparison of [11C]methionine PET, [11C]choline PET, and 4-dimensional CT as second-line scans for detection of parathyroid adenomas in primary hyperparathyroidism.
- Author
-
Noltes, Milou E., Kruijff, Schelto, Appelman, Auke P. A., Jansen, Liesbeth, Zandee, Wouter T., Links, Thera P., van Hemel, Bettien M., Schouw, Hugo M., Dierckx, Rudi A. J. O., Francken, Anne Brecht, Kelder, Wendy, van der Hoorn, Anouk, and Brouwers, Adrienne H.
- Subjects
- *
PARATHYROID glands , *POSITRON emission tomography , *COMPUTED tomography , *ADENOMA , *METHIONINE , *CHOLINE , *HYPERPARATHYROIDISM - Abstract
Purpose: Accurate preoperative localization is imperative to guide surgery in primary hyperparathyroidism (pHPT). It remains unclear which second-line imaging technique is most effective after negative first-line imaging. In this study, we compare the diagnostic effectiveness of [11C]methionine PET/CT, [11C]choline PET/CT, and four dimensional (4D)-CT head-to-head in patients with pHPT, to explore which of these imaging techniques to use as a second-line scan. Methods: We conducted a powered, prospective, blinded cohort study in patients with biochemically proven pHPT and prior negative or discordant first-line imaging consisting of ultrasonography and 99mTc-sestamibi. All patients underwent [11C]methionine PET/CT, [11C]choline PET/CT, and 4D-CT. At first, all scans were interpreted by a nuclear medicine physician, and a radiologist who were blinded from patient data and all imaging results. Next, a non-blinded scan reading was performed. The scan results were correlated with surgical and histopathological findings. Serum calcium values at least 6 months after surgery were used as gold standard for curation of HPT. Results: A total of 32 patients were included in the study. With blinded evaluation, [11C]choline PET/CT was positive in 28 patients (88%), [11C]methionine PET/CT in 23 (72%), and 4D-CT in 15 patients (47%), respectively. In total, 30 patients have undergone surgery and 32 parathyroid lesions were histologically confirmed as parathyroid adenomas. Based on the blinded evaluation, lesion-based sensitivity of [11C]choline PET/CT, [11C]methionine PET/CT, and 4D-CT was respectively 85%, 67%, and 39%. The sensitivity of [11C]choline PET/CT differed significantly from that of [11C]methionine PET/CT and 4D-CT (p = 0.031 and p < 0.0005, respectively). Conclusion: In the setting of pHPT with negative first-line imaging, [11C]choline PET/CT is superior to [11C]methionine PET/CT and 4D-CT in localizing parathyroid adenomas, allowing correct localization in 85% of adenomas. Further studies are needed to determine cost–benefit and efficacy of these scans, including the timing of these scans as first- or second-line imaging techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
57. Concomitant [18F]F-FAZA and [18F]F-FDG Imaging of Gynecological Cancer Xenografts: Insight into Tumor Hypoxia.
- Author
-
KEPES, ZITA, HEGEDUS, EVA, SASS, TAMAS, CSIKOS, CSABA, SZABO, JUDIT P., SZUGYICZKI, VIKTORIA, HAJDU, ISTVÁN, KERTESZ, ISTVAN, OPPOSITS, GABOR, IMREK, JOZSEF, BALKAY, LASZLO, KALMAN, FERENC KRISZTIÁN, and TRENCSENYI, GYORGY
- Subjects
GYNECOLOGIC cancer ,XENOGRAFTS ,RADIOPHARMACEUTICALS ,HYPOXIA-inducible factor 1 ,FLUORODEOXYGLUCOSE F18 - Abstract
Background/Aim: Herein we assessed the feasibility of imaging protocols using both hypoxia-specific [
18 F]F-FAZA and [18 F]F-FDG in bypassing the limitations derived from the non-specific findings of [18 F]F-FDG PET imaging of tumor-related hypoxia. Materials and Methods: CoCl2-generated hypoxia was induced in multidrug resistant (Pgp+) or sensitive (Pgp-) human ovarian (Pgp- A2780, Pgp+ A2780AD), and cervix carcinoma (Pgp- KB-3-1, Pgp+ KB-V-1) cell lines to establish corresponding tumor-bearing mouse models. Prior to [18 F]F-FDG/[18 F]F-FAZA-based MiniPET imaging, in vitro [18 F]F-FDG uptake measurements and western blotting were used to verify the presence of hypoxia. Results: Elevated GLUT-1, and hexokinase enzyme- II expression driven by CoCl2-induced activation of hypoxiainducible factor-1a explains enhanced cellular [18 F]F-FDG accumulation. No difference was observed in the [18 F]FFAZA accretion of Pgp+ and Pgp- tumors. Tumor-to-muscle ratios for [18 F]F-FAZA measured at 110-120 min postinjection (6.2±0.1) provided the best contrasted images for the delineation of PET-oxic and PET-hypoxic intratumor regions. Although all tumors exhibited heterogenous uptake of both radiopharmaceuticals, greater differences for [18 F]FFAZA between the tracer avid and non-accumulating regions indicate its superiority over [18 F]F-FDG. Spatial correlation between [18 F]F-FGD and [18 F]F-FAZA scans confirms that hypoxia mostly occurs in regions with highly active glucose metabolism. Conclusion: The addition of [18 F]F-FAZA PET to [18 F]F-FGD imaging may add clinical value in determining hypoxic sub-regions. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
58. Efficient Synthesis and HPLC-Based Characterization for Developing Vanadium-48-Labeled Vanadyl Acetylacetonate as a Novel Cancer Radiotracer for PET Imaging.
- Author
-
Broder, Brittany A., Bhuiyan, Mohammed, Freifelder, Richard, Rotsch, David A., Chitneni, Satish K., Makinen, Marvin W., and Chen, Chin-Tu
- Subjects
- *
RADIOACTIVE tracers , *POSITRON emission tomography , *HIGH performance liquid chromatography - Abstract
Bis(acetylacetonato)oxidovanadium(IV) [(VO(acac)2], generally known as vanadyl acetylacetonate, has been shown to be preferentially sequestered in malignant tissue. Vanadium-48 (48V) generated with a compact medical cyclotron has been used to label VO(acac)2 as a potential radiotracer in positron emission tomography (PET) imaging for the detection of cancer, but requires lengthy synthesis. Current literature protocols for the characterization of VO(acac)2 require macroscale quantities of reactants and solvents to identify products by color and to enable crystallization that are not readily adaptable to the needs of radiotracer synthesis. We present an improved method to produce vanadium-48-labeled VO(acac)2, [48V]VO(acac)2, and characterize it using high-performance liquid chromatography (HPLC) with radiation detection in combination with UV detection. The approach is suitable for radiotracer-level quantities of material. These methods are readily applicable for production of [48V]VO(acac)2. Preliminary results of preclinical, small-animal PET studies are presented. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
59. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
- Author
-
Zhu, Shiyu, Liang, Beibei, Zhou, Yuxuan, Chen, Yinfei, Fu, Jiayu, Qiu, Ling, and Lin, Jianguo
- Subjects
- *
RADIOACTIVE tracers , *PROGRAMMED cell death 1 receptors , *PROGRAMMED death-ligand 1 , *POSITRON emission tomography , *APOPTOSIS , *RADIOCHEMICAL purification , *PEPTIDES - Abstract
Purpose: Due to tumor heterogeneity, immunohistochemistry (IHC) showed poor accuracy in detecting the expression of programmed cell death ligand-1 (PD-L1) in patients. Positron emission tomography (PET) imaging is considered as a non-invasive technique to detect PD-L1 expression at the molecular level visually, real-timely and quantitatively. This study aimed to develop novel peptide-based radiotracers [68Ga]/[18F]AlF-NOTA-IMB for accurately detecting the PD-L1 expression and guiding the cancer immunotherapy. Methods: NOTA-IMB was prepared by connecting 2,2′-(7-(2-((2,5-dioxopyrrolidin-1-yl)oxy)- 2-oxoethyl)-1,4,7-triazonane-1,4-diyl) diacetic acid (NOTA-NHS) with PD-L1-targeted peptide IMB, and further radiolabeled with 68Ga or 18F-AlF. In vitro binding assay was conducted to confirm the ability of [68Ga]/[18F]AlF-NOTA-IMB to detect the expression of PD-L1. In vivo PET imaging of [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB in different tumor-bearing mice was performed, and dynamic changes of PD-L1 expression level induced by immunotherapy were monitored. Radioautography, western blotting, immunofluorescence staining and biodistribution analysis were carried out to further evaluate the specificity of radiotracers and efficacy of PD-L1 antibody immunotherapy. Results: [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB were both successfully prepared with high radiochemical yield (> 95% and > 60%, n = 5) and radiochemical purity (> 95% and > 98%, n = 5). Both tracers showed high affinity to human and murine PD-L1 with the dissociation constant (Kd) of 1.00 ± 0.16/1.09 ± 0.21 nM (A375-hPD-L1, n = 3) and 1.56 ± 0.58/1.21 ± 0.39 nM (MC38, n = 3), respectively. In vitro cell uptake assay revealed that both tracers can specifically bind to PD-L1 positive cancer cells A375-hPD-L1 and MC38 (5.45 ± 0.33/3.65 ± 0.15%AD and 5.87 ± 0.27/2.78 ± 0.08%AD at 120 min, n = 3). In vivo PET imaging and biodistribution analysis showed that the tracer [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB had high accumulation in A375-hPD-L1 and MC38 tumors, but low uptake in A375 tumor. Treatment of Atezolizumab induced dynamic changes of PD-L1 expression in MC38 tumor-bearing mice, and the tumor uptake of [68Ga]NOTA-IMB decreased from 3.30 ± 0.29%ID/mL to 1.58 ± 0.29%ID/mL (n = 3, P = 0.026) after five treatments. Similarly, the tumor uptake of [18F]AlF-NOTA-IMB decreased from 3.27 ± 0.63%ID/mL to 0.89 ± 0.18%ID/mL (n = 3, P = 0.0004) after five treatments. However, no significant difference was observed in the tumor uptake before and after PBS treatment. Biodistribution, radioautography, western blotting and immunofluorescence staining analysis further demonstrated that the expression level of PD-L1 in tumor-bearing mice treated with Atezolizumab significantly reduced about 3 times and correlated well with the PET imaging results. Conclusion: [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB were successfully prepared for PET imaging the PD-L1 expression noninvasively and quantitatively. Dynamic changes of PD-L1 expression caused by immunotherapy can be sensitively detected by both tracers. Hence, the peptide-based radiotracers [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB can be applied for accurately detecting the PD-L1 expression in different tumors and monitoring the efficacy of immunotherapy. Two novel peptide-based radiotracers [68Ga]NOTA-IMB and [18F]AlF-NOTA-IMB were developed as promising agents for evaluating the immunotherapy effect by monitoring the changes of PD-L1 expression in real time. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
60. Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors.
- Author
-
Sabeghi, Paniz, Zarand, Paniz, Zargham, Sina, Golestany, Batis, Shariat, Arya, Chang, Myles, Yang, Evan, Rajagopalan, Priya, Phung, Daniel Chang, and Gholamrezanezhad, Ali
- Subjects
- *
ULTRASONIC imaging , *MAGNETIC resonance imaging , *HUMAN fingerprints , *NUCLEAR magnetic resonance spectroscopy , *BRAIN tumors , *DIAGNOSTIC imaging , *RADIOMICS , *POSITRON emission tomography , *RADIOLOGIC technology , *PERFUSION imaging , *CENTRAL nervous system , *DIFFUSION of innovations , *PERFUSION ,BRAIN tumor diagnosis - Abstract
Simple Summary: In the realm of neurology, advanced imaging tools play a crucial role as critical endpoints in clinical trials. While magnetic resonance imaging (MRI) serves as a primary diagnostic tool, it exhibits limitations in specific scenarios. Ongoing research in neuro-oncological imaging aims to address these limitations. Our review explores the latest advancements in imaging modalities for neuro-oncology, highlighting the accuracy and competence of each modality. These include PET tracers and radiolabeled amino acids, PET/MRI, radiomics, deep learning, MR perfusion imaging, MR fingerprinting, MR spectroscopy imaging, MR elastography, and intra-operative ultrasound techniques. The focus is on the potency of these modalities in diagnosis, cancer staging, prognosis, and post-treatment evaluation, ultimately enhancing accuracy and effectiveness in managing brain tumors. This study delineates the pivotal role of imaging within the field of neurology, emphasizing its significance in the diagnosis, prognostication, and evaluation of treatment responses for central nervous system (CNS) tumors. A comprehensive understanding of both the capabilities and limitations inherent in emerging imaging technologies is imperative for delivering a heightened level of personalized care to individuals with neuro-oncological conditions. Ongoing research in neuro-oncological imaging endeavors to rectify some limitations of radiological modalities, aiming to augment accuracy and efficacy in the management of brain tumors. This review is dedicated to the comparison and critical examination of the latest advancements in diverse imaging modalities employed in neuro-oncology. The objective is to investigate their respective impacts on diagnosis, cancer staging, prognosis, and post-treatment monitoring. By providing a comprehensive analysis of these modalities, this review aims to contribute to the collective knowledge in the field, fostering an informed approach to neuro-oncological care. In conclusion, the outlook for neuro-oncological imaging appears promising, and sustained exploration in this domain is anticipated to yield further breakthroughs, ultimately enhancing outcomes for individuals grappling with CNS tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
61. The neuromodulatory role of dopamine in improved reaction time by acute cardiovascular exercise.
- Author
-
Ando, Soichi, Fujimoto, Toshihiko, Sudo, Mizuki, Watanuki, Shoichi, Hiraoka, Kotaro, Takeda, Kazuko, Takagi, Yoko, Kitajima, Daisuke, Mochizuki, Kodai, Matsuura, Koki, Katagiri, Yuki, Nasir, Fairuz Mohd, Lin, Yuchen, Fujibayashi, Mami, Costello, Joseph T., McMorris, Terry, Ishikawa, Yoichi, Funaki, Yoshihito, Furumoto, Shozo, and Watabe, Hiroshi
- Abstract
Acute cardiovascular physical exercise improves cognitive performance, as evidenced by a reduction in reaction time (RT). However, the mechanistic understanding of how this occurs is elusive and has not been rigorously investigated in humans. Here, using positron emission tomography (PET) with [11C]raclopride, in a multi‐experiment study we investigated whether acute exercise releases endogenous dopamine (DA) in the brain. We hypothesized that acute exercise augments the brain DA system, and that RT improvement is correlated with this endogenous DA release. The PET study (Experiment 1: n = 16) demonstrated that acute physical exercise released endogenous DA, and that endogenous DA release was correlated with improvements in RT of the Go/No‐Go task. Thereafter, using two electrical muscle stimulation (EMS) studies (Experiments 2 and 3: n = 18 and 22 respectively), we investigated what triggers RT improvement. The EMS studies indicated that EMS with moderate arm cranking improved RT, but RT was not improved following EMS alone or EMS combined with no load arm cranking. The novel mechanistic findings from these experiments are: (1) endogenous DA appears to be an important neuromodulator for RT improvement and (2) RT is only altered when exercise is associated with central signals from higher brain centres. Our findings explain how humans rapidly alter their behaviour using neuromodulatory systems and have significant implications for promotion of cognitive health. Key points: Acute cardiovascular exercise improves cognitive performance, as evidenced by a reduction in reaction time (RT). However, the mechanistic understanding of how this occurs is elusive and has not been rigorously investigated in humans.Using the neurochemical specificity of [11C]raclopride positron emission tomography, we demonstrated that acute supine cycling released endogenous dopamine (DA), and that this release was correlated with improved RT.Additional electrical muscle stimulation studies demonstrated that peripherally driven muscle contractions (i.e. exercise) were insufficient to improve RT.The current study suggests that endogenous DA is an important neuromodulator for RT improvement, and that RT is only altered when exercise is associated with central signals from higher brain centres. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
62. Increasing striatal dopamine release through repeated bouts of theta burst transcranial magnetic stimulation of the left dorsolateral prefrontal cortex. A 18F-desmethoxyfallypride positron emission tomography study.
- Author
-
Shaikh, Usman Jawed, Pellicano, Antonello, Schüppen, Andre, Heinzel, Alexander, Winz, Oliver H., Herzog, Hans, Mottaghy, Felix M., and Binkofski, Ferdinand
- Published
- 2024
- Full Text
- View/download PDF
63. Application of Advanced Imaging to Prostate Cancer Diagnosis and Management: A Narrative Review of Current Practice and Unanswered Questions.
- Author
-
McKone, Elizabeth L., Sutton, Elsa A., Johnson, Geoffrey B., and Phillips, Ryan M.
- Subjects
- *
CANCER diagnosis , *PROSTATE cancer , *POSITRON emission tomography , *MAGNETIC resonance imaging , *TECHNOLOGICAL innovations , *CANCER treatment - Abstract
Major advances in prostate cancer diagnosis, staging, and management have occurred over the past decade, largely due to our improved understanding of the technical aspects and clinical applications of advanced imaging, specifically magnetic resonance imaging (MRI) and prostate-cancer-specific positron emission tomography (PET). Herein, we review the established utility of these important and exciting technologies, as well as areas of controversy and uncertainty that remain important areas for future study. There is strong evidence supporting the utility of MRI in guiding initial biopsy and assessing local disease. There is debate, however, regarding how to best use the imaging modality in risk stratification, treatment planning, and assessment of biochemical failure. Prostate-cancer-specific PET is a relatively new technology that provides great value to the evaluation of newly diagnosed, treated, and recurrent prostate cancer. However, its ideal use in treatment decision making, staging, recurrence detection, and surveillance necessitates further research. Continued study of both imaging modalities will allow for an improved understanding of their best utilization in improving cancer care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
64. Synthesis and PET Imaging Biodistribution Studies of Radiolabeled Iododiflunisal, a Transthyretin Tetramer Stabilizer, Candidate Drug for Alzheimer's Disease.
- Author
-
Joshi, Sameer M., Wilson, Thomas C., Li, Zibo, Preshlock, Sean, Gómez-Vallejo, Vanessa, Gouverneur, Véronique, Llop, Jordi, and Arsequell, Gemma
- Subjects
- *
ALZHEIMER'S disease , *TRANSTHYRETIN , *DIAGNOSTIC imaging , *ORAL drug administration , *RADIOCHEMICAL purification , *URINE , *POSITRON emission tomography , *NEUROFIBRILLARY tangles - Abstract
The small-molecule iododiflunisal (IDIF) is a transthyretin (TTR) tetramer stabilizer and acts as a chaperone of the TTR-Amyloid beta interaction. Oral administration of IDIF improves Alzheimer's Disease (AD)-like pathology in mice, although the mechanism of action and pharmacokinetics remain unknown. Radiolabeling IDIF with positron or gamma emitters may aid in the in vivo evaluation of IDIF using non-invasive nuclear imaging techniques. In this work, we report an isotopic exchange reaction to obtain IDIF radiolabeled with 18F. [19F/18F]exchange reaction over IDIF in dimethyl sulfoxide at 160 °C resulted in the formation of [18F]IDIF in 7 ± 3% radiochemical yield in a 20 min reaction time, with a final radiochemical purity of >99%. Biodistribution studies after intravenous administration of [18F]IDIF in wild-type mice using positron emission tomography (PET) imaging showed capacity to cross the blood-brain barrier (ca. 1% of injected dose per gram of tissue in the brain at t > 10 min post administration), rapid accumulation in the liver, long circulation time, and progressive elimination via urine. Our results open opportunities for future studies in larger animal species or human subjects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
65. In vivo cerebral metabolic and dopaminergic characteristics in multiple system atrophy with orthostatic hypotension.
- Author
-
Xue, Chenxi, Dou, Xiaofeng, Yu, Congcong, Zhong, Yan, Wang, Jing, Zhang, Xiang, Xue, Le, Hu, Daoyan, Wu, Shuang, Zhang, Hong, and Tian, Mei
- Subjects
- *
MULTIPLE system atrophy , *ORTHOSTATIC hypotension , *TEMPORAL lobe , *POSITRON emission tomography , *TONSILS , *GLUCOSE metabolism - Abstract
Purpose: Multiple system atrophy (MSA) is a rare neurodegenerative disease, often presented with orthostatic hypotension (OH), which is a disabling symptom but has not been very explored. Here, we investigated MSA patients with OH by using positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) and 11C-N-2-carbomethoxy-3-(4-fluorophenyl)-tropane (11C-CFT) for in vivo evaluation of the glucose metabolism and dopaminergic function of the brain. Methods: Totally, 51 patients with MSA and 20 healthy controls (HC) who underwent 18F-FDG PET/CT were retrospectively enrolled, among which 24 patients also underwent 11C-CFT PET/CT. All patients were divided into MSA-OH(+) and MSA-OH(-) groups. Then, statistical parametric mapping (SPM) method was used to reveal the regional metabolic and dopaminergic characteristics of MSA-OH(+) compared with MSA-OH(-). Moreover, the metabolic networks of MSA-OH(+), MSA-OH(-) and HC groups were also constructed and analyzed based on graph theory to find possible network-level changes in MSA patients with OH. Results: The SPM results showed significant hypometabolism in the pons and right cerebellar tonsil, as well as hypermetabolism in the left parahippocampal gyrus and left superior temporal gyrus in MSA-OH(+) compared with MSA-OH(-). A reduced 11C-CFT uptake in the left caudate was also shown in MSA-OH(+) compared with MSA-OH(-). In the network analysis, significantly reduced local efficiency and clustering coefficient were shown in MSA-OH(+) compared with HC, and decreased nodal centrality in the frontal gyrus was found in MSA-OH(+) compared with MSA-OH(-). Conclusion: In this study, the changes in glucose metabolism in the pons, right cerebellar tonsil, left parahippocampal gyrus and left superior temporal gyrus were found closely related to OH in MSA patients. And the decreased presynaptic dopaminergic function in the left caudate may contribute to OH in MSA. Taken together, this study provided in vivo pathophysiologic information on MSA with OH from neuroimaging approach, which is essential for a better understanding of MSA with OH. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
66. International consensus on clinical use of presynaptic dopaminergic positron emission tomography imaging in parkinsonism.
- Author
-
Tian, Mei, Zuo, Chuantao, Cahid Civelek, A., Carrio, Ignasi, Watanabe, Yasuyoshi, Kang, Keon Wook, Murakami, Koji, Prior, John O., Zhong, Yan, Dou, Xiaofeng, Yu, Congcong, Jin, Chentao, Zhou, Rui, Liu, Fengtao, Li, Xinyi, Lu, Jiaying, Zhang, Hong, and Wang, Jian
- Subjects
- *
DOPAMINERGIC imaging , *POSITRON emission tomography , *PARKINSONIAN disorders , *PARKINSON'S disease , *IMAGE analysis - Abstract
Purpose: Presynaptic dopaminergic positron emission tomography (PET) imaging serves as an essential tool in diagnosing and differentiating patients with suspected parkinsonism, including idiopathic Parkinson's disease (PD) and other neurodegenerative and non-neurodegenerative diseases. The PET tracers most commonly used at the present time mainly target dopamine transporters (DAT), aromatic amino acid decarboxylase (AADC), and vesicular monoamine type 2 (VMAT2). However, established standards for the imaging procedure and interpretation of presynaptic dopaminergic PET imaging are still lacking. The goal of this international consensus is to help nuclear medicine practitioners procedurally perform presynaptic dopaminergic PET imaging. Method: A multidisciplinary task group formed by experts from various countries discussed and approved the consensus for presynaptic dopaminergic PET imaging in parkinsonism, focusing on standardized recommendations, procedures, interpretation, and reporting. Conclusion: This international consensus and practice guideline will help to promote the standardized use of presynaptic dopaminergic PET imaging in parkinsonism. It will become an international standard for this purpose in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
67. Breakthroughs in Alzheimer's Research: A Path to a More Promising Future?
- Author
-
Fatima, Hareer, Rangwala, Hussain Sohail, Riaz, Faiza, Rangwala, Burhanuddin Sohail, and Siddiq, Mohammad Arham
- Subjects
- *
NICOTINIC receptors , *ALZHEIMER'S disease , *CHOLINERGIC receptors , *GLIAL fibrillary acidic protein , *NICOTINIC acetylcholine receptors , *POSITRON emission tomography , *VACCINE trials - Abstract
Background: Alzheimer's disease (AD) is a widespread neurodegenerative disorder with a significant global impact, affecting approximately 50 million individuals, and projections estimate that up to 152 million people will be affected by 2050. AD is characterized by beta-amyloid plaques and tau tangles in the brain, leading to cognitive decline. Summary: Recent research on AD has made significant strides, including the development of an "amyloid clock" biomarker that tracks AD progression through positron emission tomography (PET) scans. Surf4 and other genes have been discovered to play a role in regulating beta-amyloid toxicity, while inhibiting the enzyme hexokinase-2 has shown positive results in preclinical studies. New brain mapping techniques have identified early brain-based causes of cognitive changes in AD, and biomarkers such as neuronal pentraxin protein Nptx2 and astrocytic 7-subunit of the nicotinic acetylcholine receptors (7nAChRs) show potential for early detection. Other approaches, such as replenishing the enzyme Tip60, selectively degrading the modified protein p-p38 with PRZ-18002, and targeting the protein voltage-dependent anion channel-1 (VDAC1), have shown promise in enhancing cognitive function and preventing pathophysiological alterations linked to AD. Baseline blood samples and other biomarkers such as urine formic acid, p-tau 198, microRNAs, and glial fibrillary acidic protein (GFAP) have also been discovered for early detection and intervention of AD. Additionally, recent FDA approvals for medications such as aducanumab and lecanemab provide options for reducing AD symptoms and improving function, while clinical trials for dementia vaccines show promise for the nasal and beta-amyloid 40 vaccines as well as vaccinations targeting tau. Key Messages: These advancements in AD research, including biomarker discovery and the development of disease-modifying treatments, are crucial steps towards improving the lives of those affected by AD and finding a cure for this debilitating disease. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
68. Distribution of insulin in primate brain following nose‐to‐brain transport.
- Author
-
Smith, Kylie, Fan, Jinda, Marriner, Gwendolyn A., Gerdes, John, Kessler, Robert, and Zinn, Kurt R.
- Subjects
CRIBRIFORM plate ,POSITRON emission tomography ,OLFACTORY nerve ,ALZHEIMER'S disease ,RHESUS monkeys - Abstract
Introduction: Nose‐to‐brain (N2B) insulin delivery has potential for Alzheimer's disease (AD) therapy. However, clinical implementation has been challenging without methods to follow N2B delivery non‐invasively. Positron emission tomography (PET) was applied to measure F‐18‐labeled insulin ([18F]FB‐insulin) from intranasal dosing to brain uptake in non‐human primates following N2B delivery. Methods: [18F]FB‐insulin was prepared by reacting A1,B29‐di(tert‐butyloxycarbonyl)insulin with [18F]‐N‐succinimidyl‐4‐fluorobenzoate. Three methods of N2B delivery for [18F]FB‐insulin were compared – delivery as aerosol via tubing (rhesus macaque, n = 2), as aerosol via preplaced catheter (rhesus macaque, n = 3), and as solution via preplaced catheter (cynomolgus macaque, n = 3). Following dosing, dynamic PET imaging (120 min) quantified delivery efficiency to the nasal cavity and whole brain. Area under the time‐activity curve was calculated for 46 regions of the cynomolgus macaque brain to determine regional [18F]FB‐insulin levels. Results: Liquid instillation of [18F]FB‐insulin by catheter outperformed aerosol methods for delivery to the subject (39.89% injected dose vs 10.03% for aerosol via tubing, 0.17% for aerosol by catheter) and subsequently to brain (0.34% injected dose vs 0.00020% for aerosol via tubing, 0.05% for aerosol by catheter). [18F]FB‐insulin was rapidly transferred across the cribriform plate to limbic and frontotemporal areas responsible for emotional and memory processing. [18F]FB‐insulin half‐life was longer in olfactory nerve projection sites with high insulin receptor density compared to the whole brain. Discussion: The catheter‐based liquid delivery approach combined with PET imaging successfully tracked the fate of N2B [18F]FB‐insulin and is thought to be broadly applicable for assessments of other therapeutic agents. This method can be rapidly applied in humans to advance clinical evaluation of N2B insulin as an AD therapeutic. Highlights for: [18F]FB‐insulin passage across the cribriform plate was detected by PET.Intranasal [18F]FB‐insulin reached the brain within 13 min.[18F]FB‐insulin activity was highest in emotional and memory processing regions.Aerosol delivery was less efficient than liquid instillation by preplaced catheter.Insulin delivery to the cribriform plate was critical for arrival in the brain. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
69. Neuroimaging evaluation of the long term impact of a novel paired meditation practice on brain function
- Author
-
Andrew B. Newberg, Nancy A. Wintering, Chloe Hriso, Faezeh Vedaei, Sara Gottfried, and Reneita Ross
- Subjects
cerebral metabolism ,positron emission tomography (PET) ,meditation ,brain imaging ,sexual ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
BackgroundA growing number of advanced neuroimaging studies have compared brain structure and function in long term meditators to non-meditators. The goal is to determine if there may be long term effects on the brain from practicing meditation. In this paper, we present new data on the long term effects of a novel meditation practice in which the focus is on clitoral stimulation. The findings from such a study have implications for potential therapeutic uses with regard to various neurological or psychiatric conditions.MethodsWe evaluated the cerebral glucose metabolism in 40 subjects with an extended history (>1 year of practice, 2–3 times per week) performing the meditation practice called Orgasmic Meditation (OM) and compared their brains to a group of non-meditating healthy controls (N = 19). Both meditation and non-meditation subjects underwent brain PET after injection with 148 to 296 MBq of FDG using a standard imaging protocol. Resting FDG PET scans of the OM group were compared to the resting scans of healthy, non-meditating, controls using statistical parametric mapping.ResultsThe OM group showed significant differences in metabolic activity at rest compared to the controls. Specifically, there was significantly lower metabolism in select areas of the frontal, temporal, and parietal lobes, as well as the anterior cingulate, insula, and thalamus, in the OM group compared to the controls. In addition, there were notable distinctions between the males and females with the females demonstrating significantly lower metabolism in the thalamus and insula.ConclusionsOverall, these findings suggest that the long term meditation practitioners of OM have different patterns of resting brain metabolism. Since these areas of the brain in which OM practitioners differ from controls are involved in cognition, attention, and emotional regulation, such findings have implications for understanding how this meditation practice might affect practitioners over long periods of time.
- Published
- 2024
- Full Text
- View/download PDF
70. Machine learning techniques based on 18F-FDG PET radiomics features of temporal regions for the classification of temporal lobe epilepsy patients from healthy controls
- Author
-
Kai Liao, Huanhua Wu, Yuanfang Jiang, Chenchen Dong, Hailing Zhou, Biao Wu, Yongjin Tang, Jian Gong, Weijian Ye, Youzhu Hu, Qiang Guo, and Hao Xu
- Subjects
temporal lobe epilepsy ,positron emission tomography (PET) ,radiomics ,machine learning ,18F-FDG ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
BackgroundThis study aimed to investigate the clinical application of 18F-FDG PET radiomics features for temporal lobe epilepsy and to create PET radiomics-based machine learning models for differentiating temporal lobe epilepsy (TLE) patients from healthy controls.MethodsA total of 347 subjects who underwent 18F-FDG PET scans from March 2014 to January 2020 (234 TLE patients: 25.50 ± 8.89 years, 141 male patients and 93 female patients; and 113 controls: 27.59 ± 6.94 years, 48 male individuals and 65 female individuals) were allocated to the training (n = 248) and test (n = 99) sets. All 3D PET images were registered to the Montreal Neurological Institute template. PyRadiomics was used to extract radiomics features from the temporal regions segmented according to the Automated Anatomical Labeling (AAL) atlas. The least absolute shrinkage and selection operator (LASSO) and Boruta algorithms were applied to select the radiomics features significantly associated with TLE. Eleven machine-learning algorithms were used to establish models and to select the best model in the training set.ResultsThe final radiomics features (n = 7) used for model training were selected through the combinations of the LASSO and the Boruta algorithms with cross-validation. All data were randomly divided into a training set (n = 248) and a testing set (n = 99). Among 11 machine-learning algorithms, the logistic regression (AUC 0.984, F1-Score 0.959) model performed the best in the training set. Then, we deployed the corresponding online website version (https://wane199.shinyapps.io/TLE_Classification/), showing the details of the LR model for convenience. The AUCs of the tuned logistic regression model in the training and test sets were 0.981 and 0.957, respectively. Furthermore, the calibration curves demonstrated satisfactory alignment (visually assessed) for identifying the TLE patients.ConclusionThe radiomics model from temporal regions can be a potential method for distinguishing TLE. Machine learning-based diagnosis of TLE from preoperative FDG PET images could serve as a useful preoperative diagnostic tool.
- Published
- 2024
- Full Text
- View/download PDF
71. Characterization of a novel model for atherosclerosis imaging: the apolipoprotein E-deficient rat
- Author
-
Jürgen W. A. Sijbesma, Aren van Waarde, Sebastiaan Kristensen, Ilse Kion, Uwe J. F. Tietge, Jan-Luuk Hillebrands, Marian L. C. Bulthuis, Hendrik Buikema, Dalibor Nakladal, Marit Westerterp, Fan Liu, Hendrikus H. Boersma, Rudi A. J. O. Dierckx, and Riemer H. J. A. Slart
- Subjects
Apolipoprotein E-deficient rat ,Atherosclerosis ,[18F]2-fluoro-2-deoxy-D-glucose ,Positron emission tomography (PET) ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Abstract Background The apolipoprotein E-deficient (apoE −/− ) mouse is a well-established model for studying atherosclerosis. However, its small size limits its use in longitudinal positron emission tomography (PET) imaging studies. Recently, the apoE −/− rat has emerged as an alternative. With this study, we investigate the feasibility of using apoE −/− rats as an in vivo model for longitudinal atherosclerotic PET/CT imaging. Results ApoE −/− rats showed significantly higher [18F]FDG uptake than controls in the aortic arch (+ 18.5%, p
- Published
- 2023
- Full Text
- View/download PDF
72. Microfluidic-based production of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer
- Author
-
Hemantha Mallapura, Olga Ovdiichuk, Emma Jussing, Tran A. Thuy, Camille Piatkowski, Laurent Tanguy, Charlotte Collet-Defossez, Bengt Långström, Christer Halldin, and Sangram Nag
- Subjects
Positron emission tomography (PET) ,Radiopharmaceuticals ,Microfluidics ,iMiDEV ,[68Ga]Ga-FAPI-46 ,[68Ga]Ga-DOTA-TOC ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract Background The demand for 68Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE. These tracers have exhibited promising results in theranostic applications, fueling interest in exploring them for clinical use. Among these probes, 68Ga-labeled FAPI-46 and DOTA-TOC have emerged as key players due to their ability to diagnose a broad spectrum of cancers ([68Ga]Ga-FAPI-46) in late-phase studies, whereas [68Ga]Ga-DOTA-TOC is clinically approved for neuroendocrine tumors. To facilitate their production, we leveraged a microfluidic cassette-based iMiDEV radiosynthesizer, enabling the synthesis of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC based on a dose-on-demand (DOD) approach. Results Different mixing techniques were explored to influence radiochemical yield. We achieved decay-corrected yield of 44 ± 5% for [68Ga]Ga-FAPI-46 and 46 ± 7% for [68Ga]Ga-DOTA-TOC in approximately 30 min. The radiochemical purities (HPLC) of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC were 98.2 ± 0.2% and 98.4 ± 0.9%, respectively. All the quality control results complied with European Pharmacopoeia quality standards. We optimized various parameters, including 68Ga trapping and elution, cassette batches, passive mixing in the reactor, and solid-phase extraction (SPE) purification and formulation. The developed synthesis method reduced the amount of precursor and other chemicals required for synthesis compared to conventional radiosynthesizers. Conclusions The microfluidic-based approach enabled the implementation of radiosynthesis of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC on the iMiDEV™ microfluidic module, paving the way for their use in preclinical and clinical applications. The microfluidic synthesis approach utilized 2–3 times less precursor than cassette-based conventional synthesis. The synthesis method was also successfully validated in a similar microfluidic iMiDEV module at a different research center for the synthesis of [68Ga]Ga-FAPI-46 with limited runs. Our study demonstrated the potential of microfluidic methods for efficient and reliable radiometal-based radiopharmaceutical synthesis, contributing valuable insights for future advancements in this field and paving the way for routine clinical applications in the near future.
- Published
- 2023
- Full Text
- View/download PDF
73. Good practices for the automated production of 18F-SiFA radiopharmaceuticals
- Author
-
Simon Blok, Carmen Wängler, Peter Bartenstein, Klaus Jurkschat, Ralf Schirrmacher, and Simon Lindner
- Subjects
Fluorine-18 ,Silicon fluoride acceptor ,Automation ,Positron emission tomography (PET) ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract Background The positron emitting isotope fluorine-18 (18F) possesses almost ideal physicochemical properties for the development of radiotracers for diagnostic molecular imaging employing positron emission tomography (PET). 18F in its nucleophilic anionic 18F− form is usually prepared by bombarding an enriched 18O water target with protons of various energies between 5 and 20 MeV depending on the technical specifications of the cyclotron. Large thick-target yields between 5 and 14 GBq/µA can be obtained, enough to prepare large batches of radiotracers capable to serve a considerable contingent of patients (50 + per clinical batch). The overall yield of the radiotracer however depends on the efficiency of the 18F labeling chemistry. The Silicon Fluoride Acceptor chemistry (SiFA) has introduced a convenient and highly efficient way to provide clinical peptide-based 18F-radiotracers in a kit-like procedure matching the convenience of 99mTc radiopharmaceuticals. Main body A radiotracer’s clinical success primarily hinges on whether its synthesis can be automated. Due to its simplicity, the SiFA chemistry, which is based on isotopic exchange (18F for 19F), does not only work in a manual setup but has been proven to be automatable, yielding large batches of 18F-radiotracers of high molar activity (Am). The production of SiFA radiotracer can be centralized and the radiopharmaceutical be distributed via the “satellite” principle, where one production facility economically serves multiple clinical application sites. Clinically validated tracers such as [18F]SiTATE and [18F]Ga-rhPSMA-7/-7.3 have been synthesized in an automated synthesis unit under good manufacturing practice conditions and used in large patient cohorts. Communication of common guidelines and practices is warranted to further the dissemination of SiFA radiopharmaceuticals and to give easy access to this technology. Conclusion This current review highlights the most recent achievements in SiFA radiopharmaceutical automation geared towards large batch production for clinical application. Best practice advice and guidance towards a facilitated implementation of the SiFA technology into new and already operating PET tracer production facilities is provided. A brief outlook spotlights the future potential of SiFA radiochemistry within the landscape of non-canonical labeling chemistries.
- Published
- 2023
- Full Text
- View/download PDF
74. Preparation and Preclinical Evaluation of 18F-Labeled Olutasidenib Derivatives for Non-Invasive Detection of Mutated Isocitrate Dehydrogenase 1 (mIDH1)
- Author
-
Roberta Cologni, Marcus Holschbach, Daniela Schneider, Dirk Bier, Annette Schulze, Carina Stegmayr, Heike Endepols, Johannes Ermert, Felix Neumaier, and Bernd Neumaier
- Subjects
radiofluorination ,positron emission tomography (PET) ,mIDH-selective PET tracer ,binding studies ,Organic chemistry ,QD241-441 - Abstract
Mutations of isocitrate dehydrogenase 1 (IDH1) are key biomarkers for glioma classification, but current methods for detection of mutated IDH1 (mIDH1) require invasive tissue sampling and cannot be used for longitudinal studies. Positron emission tomography (PET) imaging with mIDH1-selective radioligands is a promising alternative approach that could enable non-invasive assessment of the IDH status. In the present work, we developed efficient protocols for the preparation of four 18F-labeled derivatives of the mIDH1-selective inhibitor olutasidenib. All four probes were characterized by cellular uptake studies with U87 glioma cells harboring a heterozygous IDH1 mutation (U87-mIDH) and the corresponding wildtype cells (U87-WT). In addition, the most promising probe was evaluated by PET imaging in healthy mice and mice bearing subcutaneous U87-mIDH and U87-WT tumors. Although all four probes inhibited mIDH1 with variable potencies, only one of them ([18F]mIDH-138) showed significantly higher in vitro uptake into U87-mIDH compared to U87-WT cells. In addition, PET imaging with [18F]mIDH-138 in mice demonstrated good in vivo stability and low non-specific uptake of the probe, but also revealed significantly higher uptake into U87-WT compared to U87-mIDH tumors. Finally, application of a two-tissue compartment model (2TCM) to the PET data indicated that preferential tracer uptake into U87-WT tumors results from higher specific binding rather than from differences in tracer perfusion. In conclusion, these results corroborate recent findings that mIDH1-selective inhibition may not directly correlate with mIDH1-selective target engagement and indicate that in vivo engagement of wildtype and mutated IDH1 may be governed by factors that are not faithfully reproduced by in vitro assays, both of which could complicate development of PET probes.
- Published
- 2024
- Full Text
- View/download PDF
75. Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers
- Author
-
Joachim Strobel, Elham Yousefzadeh-Nowshahr, Katharina Deininger, Karl Peter Bohn, Christine A. F. von Arnim, Markus Otto, Christoph Solbach, Sarah Anderl-Straub, Dörte Polivka, Patrick Fissler, Gerhard Glatting, Matthias W. Riepe, Makoto Higuchi, Ambros J. Beer, Albert Ludolph, and Gordon Winter
- Subjects
Alzheimer’s disease ,frontotemporal lobar degeneration ,tauopathies ,positron emission tomography (PET) ,computed tomography (CT) ,[11C]PBB3 ,Biology (General) ,QH301-705.5 - Abstract
Accurately diagnosing Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD) is challenging due to overlapping symptoms and limitations of current imaging methods. This study investigates the use of [11C]PBB3 PET/CT imaging to visualize tau pathology and improve diagnostic accuracy. Given diagnostic challenges with symptoms and conventional imaging, [11C]PBB3 PET/CT’s potential to enhance accuracy was investigated by correlating tau pathology with cerebrospinal fluid (CSF) biomarkers, positron emission tomography (PET), computed tomography (CT), amyloid-beta, and Mini-Mental State Examination (MMSE). We conducted [11C]PBB3 PET/CT imaging on 24 patients with suspected AD or FTLD, alongside [11C]PiB PET/CT (13 patients) and [18F]FDG PET/CT (15 patients). Visual and quantitative assessments of [11C]PBB3 uptake using standardized uptake value ratios (SUV-Rs) and correlation analyses with clinical assessments were performed. The scans revealed distinct tau accumulation patterns; 13 patients had no or faint uptake (PBB3-negative) and 11 had moderate to pronounced uptake (PBB3-positive). Significant inverse correlations were found between [11C]PBB3 SUV-Rs and MMSE scores, but not with CSF-tau or CSF-amyloid-beta levels. Here, we show that [11C]PBB3 PET/CT imaging can reveal distinct tau accumulation patterns and correlate these with cognitive impairment in neurodegenerative diseases. Our study demonstrates the potential of [11C]PBB3-PET imaging for visualizing tau pathology and assessing disease severity, offering a promising tool for enhancing diagnostic accuracy in AD and FTLD. Further research is essential to validate these findings and refine the use of tau-specific PET imaging in clinical practice, ultimately improving patient care and treatment outcomes.
- Published
- 2024
- Full Text
- View/download PDF
76. Characterization of a Syngeneic Orthotopic Model of Cholangiocarcinoma by [18F]FDG-PET/MRI
- Author
-
Lena Zachhuber, Thomas Filip, Behrang Mozayani, Mathilde Löbsch, Stefan Scheiner, Petra Vician, Johann Stanek, Marcus Hacker, Thomas H. Helbich, Thomas Wanek, Walter Berger, and Claudia Kuntner
- Subjects
cholangiocarcinoma ,orthotopic ,syngeneic ,mouse model ,positron emission tomography (PET) ,magnetic resonance imaging (MRI) ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Cholangiocarcinoma (CCA) is a type of primary liver cancer originating from the biliary tract epithelium, characterized by limited treatment options for advanced cases and low survival rates. This study aimed to establish an orthotopic mouse model for CCA and monitor tumor growth using PET/MR imaging. Murine CCA cells were implanted into the liver lobe of male C57BL/6J mice. The imaging groups included contrast-enhanced (CE) MR, CE-MR with static [18F]FDG-PET, and dynamic [18F]FDG-PET. Tumor volume and FDG uptake were measured weekly over four weeks. Early tumor formation was visible in CE-MR images, with a gradual increase in volume over time. Dynamic FDG-PET revealed an increase in the metabolic glucose rate (MRGlu) over time. Blood analysis showed pathological changes in liver-related parameters. Lung metastases were observed in nearly all animals after four weeks. The study concludes that PET-MR imaging effectively monitors tumor progression in the CCA mouse model, providing insights into CCA development and potential treatment strategies.
- Published
- 2024
- Full Text
- View/download PDF
77. Dual-Tracer Positron Emission Tomography/Computed Tomography with [18F]FDG and [18F]fluorocholine in a Patient with Metastatic Parathyroid Carcinoma
- Author
-
Cesare Michele Iacovitti, Marco Cuzzocrea, Lauro Gianola, Gaetano Paone, and Giorgio Treglia
- Subjects
positron emission tomography (PET) ,nuclear medicine ,hybrid imaging ,dual-tracer ,choline ,FDG ,Medicine (General) ,R5-920 - Abstract
Here, we describe the case of a 43-year-old male patient with a metastatic parathyroid carcinoma who underwent dual-tracer whole-body positron emission tomography/computed tomography (PET/CT) with [18F]fluorocholine and fluorodeoxyglucose ([18F]FDG) for staging. [18F]FDG PET/CT detected multiple cervical and mediastinal lymph nodal lesions with increased tracer uptake, whereas [18F]fluorocholine PET/CT detected increased tracer uptake on cervical and mediastinal lymph nodal lesions and bone and lung lesions with a better evaluation of metastatic spread. Due to these imaging findings, the patient underwent systemic treatment with chemotherapy. This case demonstrates the added value of dual-tracer PET/CT in this rare metastatic tumor.
- Published
- 2024
- Full Text
- View/download PDF
78. Machine learning predictions of the adverse events of different treatments in patients with ischemic left ventricular systolic dysfunction
- Author
-
Chen, Wenjie, Liu, Jinghua, and Shi, Yuchen
- Published
- 2024
- Full Text
- View/download PDF
79. Preclinical evaluation of 68 Ga-labeled peptide CK2 for PET imaging of NRP-1 expression in vivo
- Author
-
Liu, Qingzhu, Cai, Shuyue, Ye, Jiacong, Xie, Quan, Liu, Rongbin, Qiu, Ling, and Lin, Jianguo
- Published
- 2024
- Full Text
- View/download PDF
80. Influence of reconstruction techniques on PET/CT image quality and quantitative accuracy: a phantom study
- Author
-
Su, Xuesong, Geng, Jianhua, Liu, Jianing, Liu, Fengshuo, Wu, Yichen, Zheng, Rong, and Wang, Xuejuan
- Published
- 2024
- Full Text
- View/download PDF
81. Maximum standardized uptake value in 11C-methionine positron emission tomography may predict the prognosis of patients with oral squamous cell carcinoma
- Author
-
Kuroshima, Takeshi, Kitagawa, Yoshimasa, Sato, Jun, Watanabe, Shiro, Asaka, Takuya, Abe, Takahiro, Harada, Hiroyuki, Hirata, Kenji, and Kuge, Yuji
- Published
- 2024
- Full Text
- View/download PDF
82. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer
- Author
-
Yang, Qi, Chen, Zhao, Qiu, Yongkang, Huang, Wenpeng, Wang, Tianyao, Song, Lele, Sun, Xinyao, Li, Cuicui, Xu, Xiaojie, and Kang, Lei
- Published
- 2024
- Full Text
- View/download PDF
83. Utilizing MRI, [18F]FDG-PET and [ 89Zr]Zr-DFO-28H1 FAP-PET tracer to assess inflammation and fibrogenesis in a reproducible lung injury rat model: a multimodal imaging study.
- Author
-
Boswinkel, Milou, Raavé, René, Veltien, Andor, Scheenen, Tom W.J., Petterson, Nina Fransén, in ‘t Zandt, René, Olsson, Lars E., von Wachenfeldt, Karin, Heskamp, Sandra, and Persson, Irma Mahmutovic
- Subjects
LUNG injuries ,DIAGNOSTIC imaging ,ANIMAL disease models ,MAGNETIC resonance imaging ,INTERSTITIAL lung diseases ,LUNG diseases ,PULMONARY fibrosis - Abstract
Objective: Accurate imaging biomarkers that indicate disease progression at an early stage are highly important to enable timely mitigation of symptoms in progressive lung disease. In this context, reproducible experimental models and readouts are key. Here, we aim to show reproducibility of a lung injury rat model, by inducing disease and assessing disease progression by multi-modal non-invasive imaging techniques at two different research sites. Furthermore, we evaluated the potential of fibroblast activating protein (FAP) as an imaging biomarker in the early stage of lung fibrosis. Methods: An initial lung injury rat model was set up at one research site (Lund University, Lund, Sweden) and repeated at a second site (Radboudumc, Nijmegen, The Netherlands). To induce lung injury, Sprague-Dawley rats received intratracheal instillation of bleomycin as one single dose (1,000 iU in 200 µL) or saline as control. Thereafter, longitudinal images were acquired to track inflammation in the lungs, at 1 and 2 weeks after the bleomycin challenge by magnetic resonance imaging (MRI) and [
18 F]FDG-PET. After the final [18 F]FDG-PET scan, rats received an intravenous tracer [89 Zr]Zr-DFO-28H1 (anti-FAP antibody) and were imaged at day 15, to track fibrogenesis. Upon termination, bronchoalveolar lavage (BAL) was performed to assess cell and protein concentration. Subsequently, the biodistribution of [89 Zr]Zr-DFO-28H1 was measured ex vivo and the spatial distribution in lung tissue was studied by autoradiography. Lung sections were stained, and fibrosis assessed using the modified Ashcroft score. Results: Bleomycin-challenged rats showed body weight loss and increased numbers of immune cells and protein concentrations after BAL compared with control animals. The initiation and progression of the disease were reproduced at both research sites. Lung lesions in bleomycin-exposed rats were visualized by MRI and confirmed by histology. [18 F]FDG uptake was higher in the lungs of bleomycin-challenged rats compared with the controls, similar to that observed in the Lund study. [89 Zr]Zr-DFO-28H1 tracer uptake in the lung was increased in bleomycin-challenged rats compared with control rats (p = 0.03). Conclusion: Here, we demonstrate a reproducible lung injury model and monitored disease progression using conventional imaging biomarkers MRI and [18 F]FDG-PET. Furthermore, we showed the first proof-of-concept of FAP imaging. This reproducible and robust animal model and imaging experimental set-up allows for future research on new therapeutics or biomarkers in lung disease. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
84. Microfluidic-based production of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC using the cassette-based iMiDEV™ microfluidic radiosynthesizer.
- Author
-
Mallapura, Hemantha, Ovdiichuk, Olga, Jussing, Emma, Thuy, Tran A., Piatkowski, Camille, Tanguy, Laurent, Collet-Defossez, Charlotte, Långström, Bengt, Halldin, Christer, and Nag, Sangram
- Subjects
- *
RADIOCHEMICAL purification , *CHEMICAL precursors , *SOLID phase extraction , *NEUROENDOCRINE tumors , *QUALITY control - Abstract
Background: The demand for 68Ga-labeled radiotracers has significantly increased in the past decade, driven by the development of diversified imaging tracers, such as FAPI derivatives, PSMA-11, DOTA-TOC, and DOTA-TATE. These tracers have exhibited promising results in theranostic applications, fueling interest in exploring them for clinical use. Among these probes, 68Ga-labeled FAPI-46 and DOTA-TOC have emerged as key players due to their ability to diagnose a broad spectrum of cancers ([68Ga]Ga-FAPI-46) in late-phase studies, whereas [68Ga]Ga-DOTA-TOC is clinically approved for neuroendocrine tumors. To facilitate their production, we leveraged a microfluidic cassette-based iMiDEV radiosynthesizer, enabling the synthesis of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC based on a dose-on-demand (DOD) approach. Results: Different mixing techniques were explored to influence radiochemical yield. We achieved decay-corrected yield of 44 ± 5% for [68Ga]Ga-FAPI-46 and 46 ± 7% for [68Ga]Ga-DOTA-TOC in approximately 30 min. The radiochemical purities (HPLC) of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC were 98.2 ± 0.2% and 98.4 ± 0.9%, respectively. All the quality control results complied with European Pharmacopoeia quality standards. We optimized various parameters, including 68Ga trapping and elution, cassette batches, passive mixing in the reactor, and solid-phase extraction (SPE) purification and formulation. The developed synthesis method reduced the amount of precursor and other chemicals required for synthesis compared to conventional radiosynthesizers. Conclusions: The microfluidic-based approach enabled the implementation of radiosynthesis of [68Ga]Ga-FAPI-46 and [68Ga]Ga-DOTA-TOC on the iMiDEV™ microfluidic module, paving the way for their use in preclinical and clinical applications. The microfluidic synthesis approach utilized 2–3 times less precursor than cassette-based conventional synthesis. The synthesis method was also successfully validated in a similar microfluidic iMiDEV module at a different research center for the synthesis of [68Ga]Ga-FAPI-46 with limited runs. Our study demonstrated the potential of microfluidic methods for efficient and reliable radiometal-based radiopharmaceutical synthesis, contributing valuable insights for future advancements in this field and paving the way for routine clinical applications in the near future. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
85. Radiotracers for Imaging of Inflammatory Biomarkers TSPO and COX-2 in the Brain and in the Periphery.
- Author
-
Uzuegbunam, Bright Chukwunwike, Rummel, Christoph, Librizzi, Damiano, Culmsee, Carsten, and Hooshyar Yousefi, Behrooz
- Subjects
- *
RADIOACTIVE tracers , *POSITRON emission tomography , *CYCLOOXYGENASE 2 , *TRANSLOCATOR proteins , *NON-communicable diseases , *ENCEPHALITIS , *LUNGS - Abstract
Inflammation involves the activation of innate immune cells and is believed to play an important role in the development and progression of both infectious and non-infectious diseases such as neurodegeneration, autoimmune diseases, pulmonary and cancer. Inflammation in the brain is marked by the upregulation of translocator protein (TSPO) in microglia. High TSPO levels are also found, for example, in macrophages in cases of rheumatoid arthritis and in malignant tumor cells compared to their relatively low physiological expression. The same applies for cyclooxgenase-2 (COX-2), which is constitutively expressed in the kidney, brain, thymus and gastrointestinal tract, but induced in microglia, macrophages and synoviocytes during inflammation. This puts TSPO and COX-2 in the spotlight as important targets for the diagnosis of inflammation. Imaging modalities, such as positron emission tomography and single-photon emission tomography, can be used to localize inflammatory processes and to track their progression over time. They could also enable the monitoring of the efficacy of therapy and predict its outcome. This review focuses on the current development of PET and SPECT tracers, not only for the detection of neuroinflammation, but also for emerging diagnostic measures in infectious and other non-infectious diseases such as rheumatic arthritis, cancer, cardiac inflammation and in lung diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
86. Characterization of a novel model for atherosclerosis imaging: the apolipoprotein E-deficient rat.
- Author
-
Sijbesma, Jürgen W. A., van Waarde, Aren, Kristensen, Sebastiaan, Kion, Ilse, Tietge, Uwe J. F., Hillebrands, Jan-Luuk, Bulthuis, Marian L. C., Buikema, Hendrik, Nakladal, Dalibor, Westerterp, Marit, Liu, Fan, Boersma, Hendrikus H., Dierckx, Rudi A. J. O., and Slart, Riemer H. J. A.
- Subjects
- *
CAROTID intima-media thickness , *BLOOD cholesterol , *POSITRON emission tomography , *APOLIPOPROTEIN E , *ABDOMINAL aorta , *THORACIC aorta , *RATS , *BILE acids - Abstract
Background: The apolipoprotein E-deficient (apoE−/−) mouse is a well-established model for studying atherosclerosis. However, its small size limits its use in longitudinal positron emission tomography (PET) imaging studies. Recently, the apoE−/− rat has emerged as an alternative. With this study, we investigate the feasibility of using apoE−/− rats as an in vivo model for longitudinal atherosclerotic PET/CT imaging. Results: ApoE−/− rats showed significantly higher [18F]FDG uptake than controls in the aortic arch (+ 18.5%, p < 0.001) and abdominal aorta (+ 31.0%, p < 0.001) at weeks 12, 26, and 51. ApoE−/− rats exhibited hypercholesterolemia, as evidenced by plasma cholesterol levels that were up to tenfold higher, and total hepatic cholesterol levels that were up to threefold higher than the control rats at the end of the study. Fast protein liquid chromatography cholesterol profiling indicated very high levels of pro-atherogenic apoB-containing very low-density lipoprotein and low-density lipoprotein fractions in the apoE−/− rats. Atherosclerotic lesions cover 19.9% of the surface of the aortic arch (p = 0.0013), and there was a significantly higher subendothelial accumulation of ED1-positive macrophages in the abdominal aorta of the apoE−/− rats compared to control rats (Ctrl) (p = 0.01). No differences in neutral sterols were observed but higher levels of bile acids were found in the apoE−/− rats. Conclusion: These data demonstrate early signs of hypercholesterolemia, high levels of bile acids, the development of atherosclerotic lesions, and macrophage accumulation in apoE−/− rats. Therefore, this model shows promise for atherosclerosis imaging studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
87. Preparation of 18 F-Labeled Tracers Targeting Fibroblast Activation Protein via Sulfur [ 18 F]Fluoride Exchange Reaction.
- Author
-
Craig, Austin, Kogler, Jürgen, Laube, Markus, Ullrich, Martin, Donat, Cornelius K., Wodtke, Robert, Kopka, Klaus, and Stadlbauer, Sven
- Subjects
- *
EXCHANGE reactions , *POSITRON emission tomography , *LIVER microsomes , *FIBROBLASTS , *EARLY detection of cancer , *SULFUR - Abstract
Early detection and treatment of cancers can significantly increase patient prognosis and enhance the quality of life of affected patients. The emerging significance of the tumor microenvironment (TME) as a new frontier for cancer diagnosis and therapy may be exploited by radiolabeled tracers for diagnostic imaging techniques such as positron emission tomography (PET). Cancer-associated fibroblasts (CAFs) within the TME are identified by biomarkers such as fibroblast activation protein alpha (FAPα), which are expressed on their surfaces. Targeting FAPα using small-molecule 18F-labeled inhibitors (FAPIs) has recently garnered significant attention for non-invasive tumor visualization using PET. Herein, two potent aryl-fluorosulfate-based FAPIs, 12 and 13, were synthetically prepared, and their inhibition potency was determined using a fluorimetric FAP assay to be IC50 9.63 and 4.17 nM, respectively. Radiofluorination was performed via the sulfur [18F]fluoride exchange ([18F]SuFEx) reaction to furnish [18F]12 and [18F]13 in high activity yields (AY) of 39–56% and molar activities (Am) between 20–55 GBq/µmol. In vitro experiments focused on the stability of the radiolabeled FAPIs after incubation with human serum, liver microsomes and liver cytosol. Preliminary PET studies of the radioligands were performed in healthy mice to investigate the in vivo biodistribution and 18F defluorination rate. Fast pharmacokinetics for the FAP-targeting tracers were retained and considerable bone uptake, caused by either 18F defluorination or radioligand accumulation, was observed. In summary, our findings demonstrate the efficiency of [18F]SuFEx as a radiolabeling method as well as its advantages and limitations with respect to PET tracer development. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
88. Evaluating infusion methods and simplified quantification of synaptic density in vivo with [ 11 C]UCB-J and [ 18 F]SynVesT-1 PET.
- Author
-
Asch, Ruth H, Naganawa, Mika, Nabulsi, Nabeel, Huan, Yiyun, Esterlis, Irina, and Carson, Richard E
- Abstract
For some positron emission tomography studies, radiotracer is administered as bolus plus continuous infusion (B/I) to achieve a state of equilibrium. This approach can reduce scanning time and simplify data analysis; however, the method must be validated and optimized for each tracer. This study aimed to validate a B/I method for in vivo quantification of synaptic density using radiotracers which target the synaptic vesicle glycoprotein 2 A: [11C]UCB-J and [18F]SynVesT-1. Observed mean standardized uptake values (SUV) in target tissue relative to that in plasma (C T/ C P) or a reference tissue (SUVR-1) were calculated for 30-minute intervals across 120 or 150-minute dynamic scans and compared against one-tissue compartment (1TC) model estimates of volume of distribution (V T) and binding potential (BP ND), respectively. We were unable to reliably achieve a state of equilibrium with [11C]UCB-J, and all 30-minute windows yielded overly large bias and/or variability for C T/ C P and SUVR-1. With [18F]SynVesT-1, a 30-minute scan 90–120 minutes post-injection yielded C T/ C P and SUVR-1 values that estimated their respective kinetic parameter with sufficient accuracy and precision (within 7 ± 6%). This B/I approach allows a clinically feasible scan at equilibrium with potentially better accuracy than a static scan SUVR following a bolus injection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
89. Metabolic bulk volume from FDG PET as an independent predictor of progression-free survival in follicular lymphoma.
- Author
-
Heejune So, Hyunjong Lee, Seung Hyup Hyun, Young Seok Cho, Seung Hwan Moon, Joon Young Choi, and Kyung-Han Lee
- Subjects
FOLLICULAR lymphoma ,PROGRESSION-free survival ,POSITRON emission tomography ,COMPUTED tomography ,PROGNOSIS - Abstract
Background: Total metabolic tumor volume (TMTV) in 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) predicts patient outcome in follicular lymphoma (FL); however, it requires laborious segmentation of all lesions. We investigated the prognostic value of the metabolic bulk volume (MBV) obtained from the single largest lesion. Methods: Pretreatment FDG PET/computed tomography (CT) scans of 201 patients were analyzed for TMTV and MBV using a 41% maximum standardized uptake value (SUVmax) threshold. Results: During a median follow-up of 3.2 years, 54 events, including 14 deaths, occurred. Optimal cut-offs were 121.1 cm3 for TMTV and 24.8 cm3 for MBV. Univariable predictors of progression-free survival (PFS) included a high Follicular Lymphoma International Prognostic Index 2 (FLIPI2) score, TMTV, and MBV. In the multivariable analysis, high TMTV and MBV were independent predictors of worse PFS (P =0.015 and 0.033). Furthermore, in a sub-group with FLIP2 scores of 0-2 (n = 132), high MBV could identify patients with worse PFS (P = 0.007). Conclusion: Readily measurable MBV is useful for stratifying risk in FL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
90. Positron Emission Tomography Quantitative Assessment of Off-Target Whole-Body Biodistribution of I-124-Labeled Adeno-Associated Virus Capsids Administered to Cerebral Spinal Fluid.
- Author
-
Rosenberg, Jonathan B., Fung, Edward K., Dyke, Jonathan P., De, Bishnu P., Lou, Howard, Kelly, James M., Reejhsinghani, Layla, Ricart Arbona, Rodolfo J., Sondhi, Dolan, Kaminsky, Stephen M., Cartier, Nathalie, Hinderer, Christian, Hordeaux, Juliette, Wilson, James M., Ballon, Douglas J., and Crystal, Ronald G.
- Subjects
- *
POSITRON emission tomography , *CEREBROSPINAL fluid examination , *ADENO-associated virus , *CEREBROSPINAL fluid , *CAPSIDS , *LABORATORY animals - Abstract
Based on studies in experimental animals demonstrating that administration of adeno-associated virus (AAV) vectors to the cerebrospinal fluid (CSF) is an effective route to transfer genes to the nervous system, there are increasing number of clinical trials using the CSF route to treat nervous system disorders. With the knowledge that the CSF turns over four to five times daily, and evidence in experimental animals that at least some of CSF administered AAV vectors are distributed to systemic organs, we asked: with AAV administration to the CSF, what fraction of the total dose remains in the nervous system and what fraction goes off target and is delivered systemically? To quantify the biodistribution of AAV capsids immediately after administration, we covalently labeled AAV capsids with iodine 124 (I-124), a cyclotron generated positron emitter, enabling quantitative positron emission tomography scanning of capsid distribution for up to 96 h after AAV vector administration. We assessed the biodistribution to nonhuman primates of I-124-labeled capsids from different AAV clades, including 9 (clade F), rh.10 (E), PHP.eB (F), hu68 (F), and rh91(A). The analysis demonstrated that 60–90% of AAV vectors administered to the CSF through either the intracisternal or intrathecal (lumbar) routes distributed systemically to major organs. These observations have potentially significant clinical implications regarding accuracy of AAV vector dosing to the nervous system, evoking systemic immunity at levels similar to that with systemic administration, and potential toxicity of genes designed to treat nervous system disorders being expressed in non-nervous system organs. Based on these data, individuals in clinical trials using AAV vectors administered to the CSF should be monitored for systemic as well as nervous system adverse events and CNS dosing considerations should account for a significant AAV systemic distribution. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
91. Radiosynthesis of [11C]MNS for PET imaging of NLRP3 inflammasome with [11C]nitromethane in one-pot and its evaluation in rat brains.
- Author
-
Ogata, Aya, Ikenuma, Hiroshi, Abe, Junichiro, Yamada, Takashi, Hattori, Saori, Ichise, Masanori, Suzuki, Masaaki, Kato, Takashi, and Kimura, Yasuyuki
- Subjects
- *
POSITRON emission tomography , *NLRP3 protein , *NITROMETHANE , *TAU proteins , *INFLAMMASOMES - Abstract
3,4-Methylenedioxy-β-nitrostyrene (MNS) is an inhibitor of NLRP3 (nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3) inflammasome. This inflammasome is a potential PET imaging target, because it is involved in the aggregation of amyloid-β and tau proteins in Alzheimer's disease brains. We succeeded in a challenging radio-synthesis of [11C]MNS using nitromethylenating piperonal with [11C]nitromethane (CH3NO2) in one pot. We then evaluated this ligand in rat brains. Although [11C]MNS had some moderate brain uptake and quick washout in rat brains, we were unable to detect any presence of specific binding of this ligand to NLRP3 either in vivo or in vitro. Further studies appear needed to develop more suitable radioligands for PET imaging of NLRP3. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
92. Site-specific protein conjugates incorporating Para-Azido-L-Phenylalanine for cellular and in vivo imaging.
- Author
-
Lightle, Hailey E., Kafley, Parmila, Lewis, Todd R., and Wang, Rongsheng E.
- Subjects
- *
IMMUNE checkpoint proteins , *CELL imaging , *POSITRON emission tomography , *PTEN protein , *PROTEINS , *CLAUDINS - Abstract
• Proteins of interest such as PTEN and αPD-L1 can be site-specifically labeled or conjugated using amber-suppression mediated genetic incorporation of unnatural amino acid (UAA). • Human PTEN intracellular activity can be tracked using UAA-based fluorescent imaging. • The in vivo biodistribution of the immune checkpoint protein PD-L1 can be mapped using UAA-based positron emission tomography (PET). This work features the use of amber suppression-mediated unnatural amino acid (UAA) incorporation into proteins for various imaging purposes. The site-specific incorporation of the UAA, p-azido-L-phenylalanine (pAzF), provides an azide handle that can be used to complete the strain promoted azide-alkyne click cycloaddition (SPAAC) reaction to introduce an imaging modality such as a fluorophore or a positron emission tomography (PET) tracer on the protein of interest (POI). Such methodology can be pursued directly in mammalian cell lines or on proteins expressed in vitro , thereby conferring a homogeneous pool of protein conjugates. A general procedure for UAA incorporation to use with a site-specific protein labeling method is provided allowing for in vitro and in vivo imaging applications based on the representative proteins PTEN and PD-L1. This approach would help elucidate the cellular or in vivo biological activities of the POI. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
93. Pattern of THK 5351 retention in normal aging involves core regions of resting state networks associated with higher cognitive function.
- Author
-
Yusuke Yoshida, Takamasa Yokoi, Kazuhiro Hara, Hirohisa Watanabe, Hiroshi Yamaguchi, Epifanio Bagarinao, Michihito Masuda, Toshiyasu Kato, Aya Ogura, Reiko Ohdake, Kazuya Kawabata, Masahisa Katsuno, Katsuhiko Kato, Shinji Naganawa, Nobuyuki Okamura, Kazuhiko Yanai, and Gen Sobue
- Subjects
AGING ,POSITRON emission tomography ,FUNCTIONAL connectivity ,MONOAMINE oxidase ,MAGNETIC resonance imaging - Abstract
We aimed to elucidate the distribution pattern of the positron emission tomography probe [18F]THK 5351, a marker for astrogliosis and tau accumulation, in healthy aging. We also assessed the relationship between THK5351 retention and resting state networks. We enrolled 62 healthy participants in this study. All participants underwent magnetic resonance imaging/positron emission tomography scanning consisting of T1-weighted images, resting state functional magnetic resonance imaging, Pittsburgh Compound-B and THK positron emission tomography. The preprocessed THK images were entered into a scaled subprofile modeling/principal component analysis to extract THK distribution patterns. Using the most significant THK pattern, we generated regions of interest, and performed seed-based functional connectivity analyses. We also evaluated the functional connectivity overlap ratio to identify regions with high between-network connectivity. The most significant THK distributions were observed in the medial prefrontal cortex and bilateral putamen. The seed regions of interest in the medial prefrontal cortex had a functional connectivity map that significantly overlapped with regions of the dorsal default mode network. The seed regions of interest in the putamen showed strong overlap with the basal ganglia and anterior salience networks. The functional connectivity overlap ratio also showed that three peak regions had the characteristics of connector hubs. We have identified an age-related spatial distribution of THK in the medial prefrontal cortex and basal ganglia in normal aging. Interestingly, the distribution’s peaks are located in regions of connector hubs that are strongly connected to large-scale resting state networks associated with higher cognitive function. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
94. Positron annihilation lifetime measurement with TOF-PET detectors: feasibility of Iodine-124 use.
- Author
-
Takyu, Sodai, Ikeda, Hayato, Wakizaka, Hidekatsu, Nishikido, Fumihiko, Matsumoto, Ken-ichiro, Tashima, Hideaki, Suzuki, Hisashi, Funaki, Yoshihito, Watabe, Hiroshi, Takahashi, Miwako, and Yamaya, Taiga
- Abstract
Positronium (Ps) imaging is getting attention for nuclear medicine applications, but appropriate radionuclides have not been evaluated systematically. This paper investigated the use of
124 I, which is a positron emitter with 603 keV prompt gamma ray emission with a fraction of 11.7%. The accuracy of positron annihilation lifetime measurement with124 I was compared with22 Na, which is often used in positron annihilation lifetime measurement, for certified reference materials. Results obtained with TOF-PET detectors suggested that the accuracy of the lifetime value estimation was slightly worse than that for22 Na, while the positron annihilation lifetime measurement using124 I was a feasible choice. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
95. Good practices for the automated production of 18F-SiFA radiopharmaceuticals.
- Author
-
Blok, Simon, Wängler, Carmen, Bartenstein, Peter, Jurkschat, Klaus, Schirrmacher, Ralf, and Lindner, Simon
- Subjects
- *
RADIOACTIVE tracers , *POSITRON emission tomography , *TECHNICAL specifications , *RADIOPHARMACEUTICALS , *CURRENT good manufacturing practices , *MANUAL labor - Abstract
Background: The positron emitting isotope fluorine-18 (18F) possesses almost ideal physicochemical properties for the development of radiotracers for diagnostic molecular imaging employing positron emission tomography (PET). 18F in its nucleophilic anionic 18F− form is usually prepared by bombarding an enriched 18O water target with protons of various energies between 5 and 20 MeV depending on the technical specifications of the cyclotron. Large thick-target yields between 5 and 14 GBq/µA can be obtained, enough to prepare large batches of radiotracers capable to serve a considerable contingent of patients (50 + per clinical batch). The overall yield of the radiotracer however depends on the efficiency of the 18F labeling chemistry. The Silicon Fluoride Acceptor chemistry (SiFA) has introduced a convenient and highly efficient way to provide clinical peptide-based 18F-radiotracers in a kit-like procedure matching the convenience of 99mTc radiopharmaceuticals. Main body: A radiotracer's clinical success primarily hinges on whether its synthesis can be automated. Due to its simplicity, the SiFA chemistry, which is based on isotopic exchange (18F for 19F), does not only work in a manual setup but has been proven to be automatable, yielding large batches of 18F-radiotracers of high molar activity (Am). The production of SiFA radiotracer can be centralized and the radiopharmaceutical be distributed via the "satellite" principle, where one production facility economically serves multiple clinical application sites. Clinically validated tracers such as [18F]SiTATE and [18F]Ga-rhPSMA-7/-7.3 have been synthesized in an automated synthesis unit under good manufacturing practice conditions and used in large patient cohorts. Communication of common guidelines and practices is warranted to further the dissemination of SiFA radiopharmaceuticals and to give easy access to this technology. Conclusion: This current review highlights the most recent achievements in SiFA radiopharmaceutical automation geared towards large batch production for clinical application. Best practice advice and guidance towards a facilitated implementation of the SiFA technology into new and already operating PET tracer production facilities is provided. A brief outlook spotlights the future potential of SiFA radiochemistry within the landscape of non-canonical labeling chemistries. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
96. Utility of PET-CT in Newly Diagnosed HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
- Author
-
Lee, Jaclyn, Davis, Seth J., Amin, Shaunak N., Rohde, Sarah L., and Kim, Young J.
- Subjects
- *
PAPILLOMAVIRUSES , *CHEST X rays , *POSITRON emission tomography computed tomography , *HEAD & neck cancer , *OROPHARYNGEAL cancer , *RETROSPECTIVE studies , *TUMOR classification , *COMPARATIVE studies , *PAPILLOMAVIRUS diseases , *DESCRIPTIVE statistics , *CHI-squared test , *LOGISTIC regression analysis , *SQUAMOUS cell carcinoma - Abstract
Objective: To compare the utility of positron emission tomography-computed tomography (PET-CT) versus contrasted CT neck combined with routine chest imaging for disease staging and treatment planning in human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (OPSCC) with clinically evident sites of primary disease. Methods: All adult patients with primary HPV-associated OPSCC at a single quaternary care cancer center from 2018 to 2019 were reviewed, and those with images available for re-review were included. Primary outcomes included concordance in clinical staging between the 2 imaging modalities of interest (PET-CT vs CT), as well as independent agreement of each with pathologic staging. Analysis was performed via ordinal logistic regression. A secondary outcome was treatment selection after diagnostic imaging, analyzed via chi-squared testing. Results: In total, 100 patients were included for evaluation, of which 89% were male, 91% Caucasian, and mean age was 61.2 years (SD 9.6). Clinical disease staging agreed between imaging modalities in 95% of cases (54 of 57 patients). Pathologic staging agreed with clinical staging from CT neck in 93% of cases (25 of 27 patients; P =.004), and with PET-CT in 82% (14 of 17 patients; P =.003). No differences were observed between the 2 imaging modalities for subsequent treatment selection (P =.39). Conclusion: In uncomplicated HPV-associated OPSCC, CT offers equivalent diagnostic accuracy to that of combined whole-body PET-CT for clinical staging, and has no appreciable impact on treatment selection. A reduced reliance on routine PET-CT during initial workup of HPV-associated OPSCC may be favorable for otherwise healthy patients with clinically evident sites of primary disease. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
97. Cottonseed oil alleviates ischemic stroke injury by inhibiting ferroptosis.
- Author
-
Sun, Miao, Liu, Min, Li, Qingxiao, Zhang, Xiaoying, Liu, Siyuan, Yang, Huikai, Yang, Le, Tian, Jiahe, Mi, Weidong, and Ma, Yulong
- Subjects
- *
COTTONSEED oil , *ISCHEMIC stroke , *BLOOD-brain barrier , *REPERFUSION , *REPERFUSION injury , *TRANSFERRIN receptors , *TRANSMISSION electron microscopy , *MALE models , *TRANSFERRIN - Abstract
Introduction: Ferroptosis has recently been recognized as a new cause of ischemia reperfusion injury due to blood–brain barrier (BBB) disruption followed by secondary iron‐loaded transferrin (TF) influx. As a novel and independent cell death pathway, ferroptosis was characterized by iron‐dependent lipid peroxidation, decline of GSH, GPX4, and shrinking mitochondria. Cottonseed oil (CSO), a liposoluble solvent, can alleviate ischemia stroke injuries and oxidative stress. However, the effect of CSO on ischemic stroke–induced ferroptosis has not been explored. In this study, we investigated the effect of CSO on ferroptosis caused by cerebral ischemic injury in rats. Methods: We conducted the subcutaneous injection of 1.3 mL/kg CSO every other day for 3 weeks on rats with middle cerebral artery occlusion–reperfusion (MCAO‐R) injury. We used Garcia Test, TTC staining, HE, Nissl and NeuN staining, Evans blue test, 68Ga‐citrate PET, Western blot, immunofluorescence staining, Elisa kits, and transmission electron microscopy to detect the infarct volume, neural injuries, and ferroptosis‐related indexes. Results: CSO treatment could significantly ameliorate MCAO‐R‐induced neurological dysfunction in a male rat model. Furthermore, it reduced infarct volume and neuronal injuries; protected BBB integrity; reduced the influx of iron ion, TF, and TF receptors; up‐regulated anti‐ferroptosis proteins (GPX4, xCT, HO1, FTH1), while down‐regulating ferroptosis‐related protein ACSL4; increased the activity of GSH and SOD; and decreased MDA and LPO levels. Mitochondrial destruction induced by ischemic stroke was also alleviated by CSO treatment. Conclusion: CSO treatment can alleviate ischemic stroke injury via ferroptosis inhibition, which provides a new potential therapeutic mechanism for CSO neuroprotection against ischemic stroke. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
98. PET/CT-identified atrial hypermetabolism is an index of atrial inflammation in patients with atrial fibrillation.
- Author
-
Kupusovic, J., Weber, M., Bruns, F., Kessler, L., Pesch, E., Bohnen, J., Dobrev, D., Rassaf, T., Wakili, R., Rischpler, C., and Siebermair, J.
- Abstract
Copyright of Journal of Nuclear Cardiology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
- Full Text
- View/download PDF
99. Visualization of fibroblast activation using 68Ga-FAPI PET/CT after pulmonary vein isolation with pulsed field compared with cryoballoon ablation.
- Author
-
Kupusovic, Jana, Kessler, Lukas, Bruns, Florian, Bohnen, Jan-Eric, Nekolla, Stephan G., Weber, Manuel M., Lauenroth, Anna, Rattka, Manuel, Hermann, Ken, Dobrev, Dobromir, Rassaf, Tienush, Wakili, Reza, Rischpler, Christoph, and Siebermair, Johannes
- Abstract
Background: Pulsed-field ablation (PFA) is a novel ablation modality for atrial fibrillation (AF) ablating myocardium by electroporation without tissue-heating. With its different mechanism of tissue ablation, it is assumed that lesion creation is divergent to thermal energy sources.
68 Ga-fibroblast-activation protein inhibitor (FAPI) PET/CT targets FAP-alpha expressed by activated fibroblasts. We aimed to assess68 Ga-FAPI uptake in pulmonary veins as surrogate for ablation damage after PFA and cryoballoon ablation (CBA). Methods: 26 patients (15 PFA, 11 CBA) underwent68 Ga-FAPI-PET/CT after ablation. Standardized uptake values (SUV) and fibroblast-activation volumes of localized tracer uptake were assessed. Results: Patient characteristics were comparable between groups. In PFA, focal FAPI uptake was only observed in 3/15 (20%) patients, whereas in the CBA cohort, 10/11 (90.9%) patients showed atrial visual uptake. We observed lower values of SUVmax (2.85 ± 0.56 vs 4.71 ± 2.06, P = 0.025) and FAV (1.13 ± 0.84 cm3 vs 3.91 ± 2.74 cm3 , P = 0.014) along with a trend towards lower SUVpeak and SUVmean in PFA vs CBA patients, respectively. Conclusion: Tissue response with respect to fibroblast activation seems to be less pronounced in PFA compared to established thermal ablation systems. This functional assessment might contribute to a better understanding of lesion formation in thermal and PFA ablation potentially contributing to better safety outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
100. Characterizing the binding of TC-5619 and encenicline on the alpha7 nicotinic acetylcholine receptor using PET imaging in the pig
- Author
-
Janus H. Magnussen, Anders Ettrup, Szabolcs Lehel, Dan Peters, Agnete Dyssegaard, Morten S. Thomsen, Jens D. Mikkelsen, and Gitte M. Knudsen
- Subjects
positron emission tomography (PET) ,alpha7 ,nicotinic acetylcholine receptors ,autoradiography ,occupancy study ,cognitive impairment ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
The alpha7 nicotinic acetylcholine receptor (α7-nAChR) has has long been considered a promising therapeutic target for addressing cognitive impairments associated with a spectrum of neurological and psychiatric disorders, including Alzheimer's disease and schizophrenia. However, despite this potential, clinical trials employing α7-nAChR (partial) agonists such as TC-5619 and encenicline (EVP-6124) have fallen short in demonstrating sufficient efficacy. We here investigate the target engagement of TC-5619 and encenicline in the pig brain by use of the α7-nAChR radioligand 11C-NS14492 to characterize binding both with in vitro autoradiography and in vivo occupancy using positron emission tomography (PET). In vitro autoradiography demonstrates significant concentration-dependent binding of 11C-NS14492, and both TC-5619 and encenicline can block this binding. Of particular significance, our in vivo investigations demonstrate that TC-5619 achieves substantial α7-nAChR occupancy, effectively blocking approximately 40% of α7-nAChR binding, whereas encenicline exhibits more limited α7-nAChR occupancy. This study underscores the importance of preclinical PET imaging and target engagement analysis in informing clinical trial strategies, including dosing decisions.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.